Abstract: Objective:To explore the efficacy and adverse effects of docetaxel combined with capecitabine on the basis of anthracycline in the treatment of breast cancer patient on the basis of anthracycline, and to provide evidence-based medicine evidence for the clinical application of capecitabine. Methods:PubMed, EMBase, CNKI, VIP and Wanfang database were used to search the randomized controlled trials in which the breast cancer patients were treated by docetaxel combined with capecitabine and docetaxel alone. The qualities of the included studies were assessed by the modified Jadad scale. The effective data were extracted and the pathologic complete remission (pCR), recurrence-free survival (RFS), disease-free survival (DFS) and safety were evaluated by RevMan 5.3 software. Results:A total of 10 articles were included, including 12 012 patients. The Meta-analysis results showed that there were no statistically significant differences in pCR (RR=1.04, 95%CI:0.91-1.18, P=0.59),RFS(RR=0.86, 95%CI:0.71-1.03,P=0.10) and DFS(RR=0.98, 95%CI:0.86-1.11,P=0.71) between docetaxel combined with capecitabine and docetaxel alone. The clinical safety analysis results showed that the patients treated with docetaxel combined with capecitabine were susceptible to hand-foot syndrome (OR=7.13, 95%CI:4.76-10.69, P<0.001) and stomatitis (OR=1.93, 95%CI:1.10-3.40, P=0.02). Conclusion:On the basis of anthracycline treatment, the efficacies of docetaxel combined with capecitabine and docetaxel alone in the treatment of the breast cancer patients are similar. The former is more likely to cause the hand-foot syndrome and stomatitis.

Key words: breast neoplasms, Meta-analysis, docetaxel, capecitabine